Category Innovation/ R&D

India Proposes Expediting Patents For Women, Small Entities, Waiving PCT Fees

The Indian Ministry of Commerce and Industry from the Department of Industrial Policy and Promotion recently published draft amendments to the Patent Rules of 2003 that would expand the eligibility for expedited examination of patent applications to include women and small entities, and would waive the fees for online filing of international patent applications through the Patent Cooperation Treaty (PCT), among other changes.

Do Patent Trolls Exist? Two Studies Reach Different Conclusions (Part 2)

Two recent academic papers examine whether Non-Practicing Entities (NPEs) deserve their reputation as patent trolls – but the papers reach conflicting conclusions. As discussed in the first part of this article, a paper published by Stanford’s Hoover Institution found that 26 publicly-listed NPEs invest in R&D and do little harm to America’s high tech sector. These findings, however, are less significant than they appear. Another paper, published by Harvard Business School (HBS), found that NPEs do on average behave as patent trolls. How important – and trustworthy – are the HBS findings?

Singapore IP Office Grants First Accelerated Patent Under New FinTech Initiative

The Intellectual Property Office of Singapore (IPOS) has granted its first accelerated patent under its new FinTech Fast Track initiative last week to Voyager Innovations, a technology company based in Southeast Asia, according to an IPOS press release. “While patent…

The Future Of The Ideas Business – The Rise Of Data-Driven Invention

New ideas are getting harder to find, and with less ideas there is a decline in organisational productivity and economic growth. This isn’t new, nor is the fact that to counterbalance the decline in idea generation, research and development have received and continue to require heavy investment. But with daily news of innovation centres opening up across the globe, the question remains whether initiatives like open innovation, crowdsourcing, or simply putting more scientific brains together will do this investment justice.

Last month, leading representatives of the IP, R&D and technology arenas met in Switzerland to discuss a technology-based alternative to human only idea generation. Hosted by data-driven invention company Iprova, the 2nd Data-Driven Invention Forum saw attendees from companies, such as Panasonic, Philips and DuPont as well as many other global organisations explore the future of innovation and the role data-driven invention plays in it. Here are some of the conclusions of the conference.

Licensing Experts Share Experiences At WIPO

Voluntary licences are cited by some as the best way to facilitate access to medicines. Terms of the licences are important, many factors have to be taken into consideration, and the earlier the better, as explained by licencing experts at the World Intellectual Property Organization this week.

OECD Report Presents Policies To Balance Innovation With Access To Medicines

The Organisation for Economic Cooperation and Development (OECD) has released a new report that presents policy options for countries to strike a better balance between promoting financial incentives for pharmaceutical innovation and ensuring affordable access to medicines. Finding this balance, the report explains, will be essential for ensuring the sustainability of health systems.

As Blockchain Inventions Explode, EPO Says It’s Ready To Meet Patent Demand

THE HAGUE, NETHERLANDS -- The number of blockchain inventions is mushrooming, and the European Patent Office wants to ensure it handles the increasing patent applications consistently, officials said at a 4 December conference that brought together around 350 patent examiners and practitioners.

US IP Stakeholders Seek To Strengthen Public Support For IP, Ensure Future US Competitiveness

NEW YORK -- United States intellectual property stakeholders from academic, business and legal backgrounds gathered recently to discuss how to increase public support to strengthen the intellectual property rights system in the US, in light of China’s steady rise in numbers of patent and trademark filings. US IP stakeholders argued that developing public awareness and understanding of IP is key to building this support, with some holding diverging views on how to go about this.

Study Finds Arthritis Drug Enbrel Overpatented, Overpriced in US

Initiative for Medicines, Access & Knowledge (I-MAK) released a new study yesterday showing that the rheumatoid arthritis drug Enbrel has been overpatented by drugmaker Amgen, which has filed a total of 57 patents on the drug in the United States. Together, these patents were said to delay market competition by 39 years, rather than the standard 20 years for one patent. The study found that this market exclusivity for Enbrel resulted in US$ 8 billion dollars in sales in 2017 alone.

WHO Director Tedros Gives Thoughts On Access To Medicines, Gene Editing, Ebola

World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) met with United Nations journalists today, in what he said would become a regular end-of-the-year meeting with the press. He gave an update on the ongoing Ebola outbreak and his views on the recent human gene editing by a Chinese researcher, and on the use of gene drive organisms to fight malaria. He also provided his views on access to affordable and safe medicines.